237 related articles for article (PubMed ID: 23839541)
21. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].
Szucs TD; Guggenberger G; Berger K; März W; Schäfer JR
Herz; 1998 Aug; 23(5):319-29. PubMed ID: 9757381
[TBL] [Abstract][Full Text] [Related]
22. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
[TBL] [Abstract][Full Text] [Related]
24. Does higher usage of low-cost statins correlate with a poorer achievement in cholesterol quality markers for secondary prevention?
Hickman J
Br J Gen Pract; 2010 Jan; 60(570):50-2. PubMed ID: 20040169
[TBL] [Abstract][Full Text] [Related]
25. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
Blake GJ; Ridker PM; Kuntz KM
Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Troche CJ; Tacke J; Hinzpeter B; Danner M; Lauterbach KW
Eur Heart J; 1998 Apr; 19 Suppl C():C59-65. PubMed ID: 9597427
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Grover SA; Coupal L; Paquet S; Zowall H
Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
[TBL] [Abstract][Full Text] [Related]
29. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
Tonelli M; Moyé L; Sacks FM; Kiberd B; Curhan G;
Ann Intern Med; 2003 Jan; 138(2):98-104. PubMed ID: 12529091
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
[TBL] [Abstract][Full Text] [Related]
31. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
32. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
[TBL] [Abstract][Full Text] [Related]
34. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
36. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
38. Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).
Lloyd SM; Stott DJ; de Craen AJ; Kearney PM; Sattar N; Perry I; Packard CJ; Briggs A; Marchbank L; Comber H; Jukema JW; Westendorp RG; Trompet S; Buckley BM; Ford I
PLoS One; 2013; 8(9):e72642. PubMed ID: 24023757
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia - An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS).
Kodera S; Morita H; Kiyosue A; Ando J; Komuro I
Circ J; 2018 Mar; 82(4):1076-1082. PubMed ID: 29367520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
